Type 2 Inflammation is the underlying cause of CRSwNP in 80% of Patients.
IL-4 and IL-13 have distinct and overlapping roles with a broad impact on CRSwNP symptoms.
.jpg/jcr:content/image%20(7).jpg)
.webp/jcr:content/11%20(2).webp)
.webp/jcr:content/10%20(3).webp)
MAT-BH-2400335/v1/May2024
Campus
Campus
IL-4 and IL-13 have distinct and overlapping roles with a broad impact on CRSwNP symptoms.
By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.